December 01, 2020
A recently launched Massachusetts biotech startup stole detailed lung cancer drug research from a Dana-Farber Cancer Institute-linked firm amid due diligence discussions through bad-faith dealings and "brazen fraud," according to a federal lawsuit filed Monday.